🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Platinum-resistant Ovarian Cancer

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer NCT05998135Phase 21 site📍 Atlanta Emory University · Tests: Atovaquone, Biopsy, Computed Tomography, Paracentesis GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer NCT07489287Phase 11 site📍 Buffalo Roswell Park Cancer Institute · Tests: GB-5267 - IV only, GB-5267 -Combined IV and IP Infusion MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer NCT06483048Phase 11 site📍 Scottsdale Mayo Clinic · Tests: Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection, Computed Tomography, Cyclophosphamide A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients NCT06522828Phase 21 site📍 Chongqing Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Tests: SSGJ-707, carboplatin, paclitaxel A Study of SHR-A1811 in Subjects With Ovarian Cancer NCT06828354Phase 32 sites📍 Wuhan📍 Jinan Jiangsu HengRui Medicine Co., Ltd. · Tests: SHR-A1811, Paclitaxel Injection, Doxorubicin Hydrochloride Liposome Injection, Gemcitabine Hydrochloride for Injection,… Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers NCT06906341Phase 249 sites📍 Birmingham📍 Palo Alto📍 San Francisco Corcept Therapeutics · Tests: Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression NCT07214779Phase 3198 sites📍 Anchorage📍 Tucson📍 Duarte Incyte Corporation · Tests: INCB123667, Investigator's choice of chemotherapy A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer NCT07042802Phase 1, Phase 213 sites📍 Beijing📍 Beijing📍 Fuzhou Nanjing Leads Biolabs Co.,Ltd · Tests: LBL-024 for Injection, Paclitaxel injection, Bevacizumab injection Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer NCT05538091Phase 21 site📍 Pittsburgh Ronald Buckanovich · Tests: Vismodegib, Atezolizumab SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer NCT06394492Phase 32 sites📍 Beijing📍 Hangzhou Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-A1921, Doxorubicin, Paclitaxel, Topotecan Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655Phase 1, Phase 215 sites📍 Los Angeles📍 Grand Rapids📍 New York Exscientia AI Ltd., a wholly owned subsidiary of Recursion … · Tests: GTAEXS617, SoC Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer. NCT05753826Phase 21 site📍 Fujian Fujian Cancer Hospital · Tests: Adebrelimab, Fuzuloparib Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer NCT05636111Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Paclitaxel, Bevacizumab, Lurbinectedin APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST NCT06687070Phase 11 site📍 Guangzhou Ascentage Pharma Group Inc. · Tests: APG -2449, PLD A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers NCT07708753Phase 31 site📍 Beijing CSPC Megalith Biopharmaceutical Co.,Ltd. · Tests: SYS6043, Liposomal doxorubicin, paclitaxel, or topotecan A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors NCT06515613Phase 115 sites📍 Little Rock📍 Beverly Hills📍 Denver Context Therapeutics Inc. · Tests: CTIM-76 Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer NCT04921527Phase 31 site📍 Shanghai Chipscreen Biosciences, Ltd. · Tests: chiauranib, Placebo, Paclitaxel A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer NCT06710288Phase 22 sites📍 El Segundo📍 Newport Beach ImmunityBio, Inc. · Tests: Gemcitabine, N-803, M-CENK Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer NCT06321484Phase 12 sites📍 Boston📍 Boston Dana-Farber Cancer Institute · Tests: Cytokine-Induced Memory-like Natural Killer Cells, Interleukin 2 A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine NCT03854110Phase 14 sites📍 Chicago📍 Fairway📍 Boston Persevere Therapeutics Inc. · Tests: misetionamide (also known as GP-2250) A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors NCT05914116Phase 1, Phase 2107 sites📍 Tucson📍 Los Angeles📍 Los Angeles DualityBio Inc. · Tests: DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide, Abiraterone Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer. NCT06660511EARLY Phase 11 site📍 Changsha Second Xiangya Hospital of Central South University · Tests: Disitamab Vedotin in Combination With Anlotinib Hydrochloride DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer NCT06964009Phase 13 sites📍 Boston📍 Boston📍 Boston Elizabeth Stover, MD, PhD · Tests: DT2216, Paclitaxel Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. NCT07755436Phase 16 sites📍 Orlando📍 Boston📍 Nashville ArriVent BioPharma, Inc. · Tests: ARR-002 A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. NCT07470853Phase 112 sites📍 Little Rock📍 Los Angeles📍 Sarasota Whitehawk Therapeutics, Inc. · Tests: HWK-016, MUCIN-16-targeted ADC, Bevacizumab A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470Phase 112 sites📍 Los Angeles📍 Grand Rapids📍 Lake Success MacroGenics · Tests: MGC026 Dose Escalation, MGC026 Dose for Expansion A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer NCT07226427Phase 115 sites📍 Springdale📍 New Haven📍 Sarasota Stemline Therapeutics, Inc. · Tests: MEN2501 HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer NCT06855069Phase 31 site📍 Beijing Hansoh BioMedical R&D Company · Tests: HS-20089, Paclitaxel, Doxorubicin, Topotecan CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. NCT06690775Phase 266 sites📍 Phoenix📍 Tucson📍 Duarte TORL Biotherapeutics, LLC · Tests: TORL-1-23, TORL-1-23, TORL-1-23, Pegfilgrastim (drug) Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites📍 Phoenix📍 Tucson📍 Los Angeles Genmab · Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy